Psoriatic arthritis. Clinical guidelines for diagnosis and treatment

Коротаева, Т. В.; Корсакова, Ю. Л.; Логинова, Е. Ю.; Gubar, E.; Chamurlieva, M.

doi:10.14412/1996-7012-2018-2-22-35

Cited by 25 publications

(15 citation statements)

References 19 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Различия клинического течения псориатического артрита у детей разных возрастов объясняются продолжающимися процессами созревания иммунной системы, разницей в количестве циркулирующих клеток иммунитета и цитокинов, а также возрастными особенностями микробиома кишечника [50][51][52]. В диагностике псориатического артрита используют критерии CASPAR [53,54]. Кроме того, Международная ассоциация ревматологов рекомендует учитывать последние диагностические и классификационные критерии ювенильных артритов Педиатрической ревматологической международной организации по клиническим исследованиям (PRINTO -Paediatric Rheumatology International Trials Organisation) [53].…”

Section: псориатический артритunclassified

“…Из-за отсутствия специфических лабораторных маркеров болезни физикальное обследование и использование специальных опросников у детей и родителей (опросник PEST, разработанный G. Н. Ibrahim и соавт.) являются основными методами ранней диагностики псориатического артрита [27,54,55]. Кроме того, псориатический артрит может быть ассоциирован с развитием увеита (в 1,5-25% случаев развития заболевания), что обусловливает необходимость скрининга офтальмологической патологии у соответствующего специалиста и выявления боли, покраснения глаз, фотофобии, миоза и снижения остроты зрения [56].…”

Section: псориатический артритunclassified

See 1 more Smart Citation

Psoriasis Comorbidities in Childhood

Мурашкин

Круглова

Коваленко

et al. 2020

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

Psoriasis is multifactorial systemic disease characterized by excessive hyperkeratosis due to impaired keratinocytes proliferation and differentiation. This disease often manifests in childhood and it is usually associated with the development of comorbid conditions some of which are combined by the term «psoriatic march» (obesity, metabolic syndrome, etc.). The course of psoriasis and related comorbidities in children has several specific features that determine topicality of studying all the aspects of clinical diagnosis and prevention in childhood. The article summarizes recent ideas on the prevalence, pathogenesis features and early diagnosis of comorbid diseases in children with psoriasis.

show abstract

Section: псориатический артритunclassified

Psoriasis Comorbidities in Childhood

Мурашкин

Круглова

Коваленко

et al. 2020

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

show abstract

“…Псориатический артрит (ПсА) -хроническое воспалительное заболевание суставов, позвоночника и энтезисов, которое часто развивается у больных с кожным псориазом. При ПсА главным образом наблюдается воспаление периферических суставов (артрит), сухожилий пальцев кистей и стоп (теносиновит, дактилит), энтезисов (энтезит), которое нередко может сочетаться с воспалением в аксиальных структурах -телах позвонков (спондилит) и крестцовоподвздошных суставах (сакроилиит) [1].…”

unclassified

“…ПсА страдает от 0,001 до 1,5% населения, его выявляют у 6,25-48% пациентов с псориазом [1]. Согласно данным статистической отчетности Минздрава России, в 2017 г. в Российской Федерации с диагнозом «псориатический артрит (псориаз артропатический)» было зарегистрировано 19 843 человека, из них 19 442 взрослых в возрасте 18 лет и старше (13,52 и 16,58 на 100 тыс.…”

unclassified

Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system

Пядушкина

Derkach

Frolov

et al. 2021

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Objective: to evaluate the economic impact of the use of various biologic disease-modifying antirheumatic drugs (bDMARDs) from the group of inhibitors of interleukins (iIL) 12/23 and iIL17 in adult patients with psoriatic arthritis (PsA) with insufficient response to therapy with TNFα inhibitors (TNFα inhibitors).Patients and methods. A Microsoft Excel model has been developed, it allows to calculate the average cost of treatment of 1 patient with PsA who needs a second-line bDMARD from the iIL12/23 or iIL17 group. Only direct medical costs (drug costs) were considered. Cost minimization analysis and budget impact analysis were carried out.Results and discussion. The results of a network meta-analysis demonstrate no statistically significant differences in efficacy and safety between ixekizumab (IXE) and secukinumab (SEC) and superiority SEC over ustekinumab when used in adult patients with active PsA with insufficient response to or intolerance of previous therapy with synthetic disease-modifying antirheumatic drugs or TNFα inhibitors. The analysis of cost minimization showed that the total cost of 1 patient managing for 1 year using IXE is 26% lower than treatment with SEC: on a 2 year horizon, the difference is 27%. Analysis of the impact on the budget revealed that on the horizon of 1 year the simulated distribution will lead to budget savings of 16,796,131 rubles, which will allow additional treatment of 17 patients with IXE, after 2 years the budget savings will amount to 39,289,373 rubles, which will allow to treat additionally 52 patients. The sensitivity analysis confirmed the robustness of the study results.Conclusion. Thus, in adult patients with PsA requiring second-line bDMARDs, the use of IXE is more effective than the use of SEC and provides reduction in direct medical costs. The use of IXE will not have a significant impact on costs under the State Guarantee Program, but it can increase the availability of bDMARDs in patients with active PsA who have not responded to the previous therapy, without increasing the budget.

show abstract

“…Псориатический артрит (ПсА) -хроническое иммуноопосредованное заболевание из группы спондилоартритов (СпА), характеризующееся поражением опорнодвигательного аппарата с широким спектром различных клинических проявлений, обычно ассоциированное с псориазом. В клинической картине превалируют воспаление периферических суставов (артрит), энтезисов (энтезит) и сухожилий пальцев кистей и стоп (теносиновит, дактилит), поражение осевого скелета (позвоночника и крестцово-подвздошных сочленений), из внесуставных проявлений характерно поражение кожи, ногтей и органа зрения (увеит) [1].…”

unclassified

Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis

Dadalova

Vasilenko

Самигуллина

et al. 2020

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is a chronic immune-mediated disease from a group of spondyloarthritis, which is characterized by damage to the musculoskeletal system with a wide range of different clinical manifestations and is usually associated with psoriasis. Activation of the interleukin (IL) 23/IL17 axis plays a key role in the pathogenesis of PsA and psoriasis. When non-steroidal and synthetic disease-modifying antirheumatic drugs are insufficiently effective, biological drugs are recommended. In recent years, there have been considerable advances in PsA treatment with tumor necrosis factor-α (IFN-α) inhibitors and IL-12/23 inhibitors. However, in some cases, this therapy fails to provide the desired effect and a search for new treatments for PsA seems to be an urgent task. The paper desctibes a clinical case demonstrating the efficacy of the IL17A inhibitor ixekizumab in a patient with high PsA activity and recurrent uveitis in both eyes. Ixekizumab therapy resulted in positive changes as the reduced severity of articular syndrome and psoriasis and normalization of acute phase parameters. Assessing the activity of PsA over time when using ixekizumab during a year showed an average decrease in ESR from 72 to 19 mm/h, in CRP from 162.1 to 0 mg/L, BSA from 51 to 0.25%, PASI from 43. 6 to 0, DAPSA from 78.2 to 2, ASDAS-SRB from 5.11 to 1.12, BASDAI from 4.85 to 1, BASFI from 5.3 to 0.7, BASMI from 5.0 to 2.6, MASES from 6 to 0, LEI from 2 to 0, SPARCC from 6 to 0, and NAPSI from 28 to 8. Thus, this clinical case is an example of successful treatment with the IL17 inhibitor ixekizumab for PsA with recurrent uveitis in the patient who has previously received three drugs from the TNFα group without any effect.

show abstract

Psoriatic arthritis. Clinical guidelines for diagnosis and treatment

Cited by 25 publications

References 19 publications

Psoriasis Comorbidities in Childhood

Psoriasis Comorbidities in Childhood

Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system

Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis

Contact Info

Product

Resources

About